Company profile
INTEGRA LIFESCIENCES HOLDINGS CORP
NASDAQ:IARTMedical/Dental Instruments
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ACLERASTIDE | phase3 | — | 2 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02482948 | — | terminated | 2015-06-01 | 2017-03-01 | Integra LifeSciences Corporation | MEDIHONEY® Gel Versus Collagenase for Wound Debridement |
| NCT01840085 | phase3 | terminated | 2015-12-01 | 2015-12-01 | Integra LifeSciences Corporation | Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use |
| NCT01849965 | phase3 | terminated | 2013-04-01 | 2015-12-01 | Integra LifeSciences Corporation | Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers |
| NCT01830348 | phase3 | terminated | 2013-02-01 | 2015-12-01 | Integra LifeSciences Corporation | Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers |
FDA applications (0)
No records yet.